文献速递痛风与晶体性关节病

美国退伍军人健康管理局痛风发病率、患病率及负担研究

Incidence, Prevalence, and Burden of Gout in the Veterans Health Administration.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2021-08-02

该研究基于美国退伍军人健康管理局(VHA)1999至2014年全国数据,分析2005至2014年痛风患病率、发病率及负担。结果显示痛风患病率从4.2%升至5.8%,发病率5.8–7.4例/1000患者年,2014年46%痛风患者接受降尿酸治疗,弱阿片类药物使用率从2005年近乎翻倍至16.4%。

要点

  • 2005至2014年VHA痛风患病率由4.2%升至5.8%,发病率5.8–7.4例/1000患者年。
  • 2014年46%痛风患者接受降尿酸治疗,10年间保持稳定。
  • 2014年16.4%痛风患者使用弱阿片类药物,较2005年近乎翻倍。

核心结论

  • VHA痛风负担显著且在2005至2014年间增加,降尿酸治疗使用稳定而阿片类药物使用增加。

主要发现

  • 痛风患病率从2005年4.2%升至2014年5.8%,发病率范围为5.8至7.4例/1000患者年。
  • 患病率在男性、老年患者及非西班牙裔黑人患者中最高。
  • 2014年4.0%的住院或门诊就诊及1.3%的住院与痛风相关。
  • 2014年46%痛风患者接受降尿酸治疗,10年间保持稳定。
  • 2014年16.4%现患痛风患者使用弱阿片类药物,较2005年近乎翻倍,强阿片类药物使用无显著变化。

关键数值与推荐

  • 痛风患病率从2005年4.2%增至2014年5.8%,发病率5.8–7.4例/1000患者年。
  • 2014年46%痛风患者接受降尿酸治疗,16.4%使用弱阿片类药物。

临床怎么用

  • VHA痛风负担持续增加,应关注降尿酸治疗覆盖率及阿片类药物在痛风患者中的使用趋势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the prevalence, incidence, and burden of gout in the Veterans Health Administration (VHA) from 2005 to 2014. METHODS: We used national VHA data from January 1999 to December 2014 to determine the annual incidence and prevalence of gout in the VHA. Gout burden to the VHA was determined by the proportion of patients with an encounter related to gout. Rates of urate-lowering therapy (ULT) and opiate use were determined annually. Characteristics of those with and without gout were compared using 2014 data. RESULTS: From 2005 to 2014, gout prevalence in the VHA increased from 4.2% to 5.8%, while disease incidence ranged from 5.8 to 7.4 cases per 1,000 patient-years. Gout prevalence was highest among men, older patients, and non-Hispanic black patients. During 2014, 4.0% of all inpatient or outpatient encounters and 1.3% of hospitalizations were gout related. Administration of ULT remained stable over the 10-year period, with 46% of gout patients receiving ULT in 2014. In contrast, 16.4% of prevalent gout patients were receiving a weak opioid in 2014, nearly doubling the prescription rate of weak opioids in 2005, while the use of stronger opioids did not change significantly over this period. Patients with gout had greater comorbidity and health care utilization than patients without gout. CONCLUSION: The burden posed by gout in the VHA is considerable and increased between 2005 and 2014. While the use of ULT has remained stable, the use of opioid therapy has increased among patients with gout.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Helget LN, England BR, Roul P, et al. Incidence, Prevalence, and Burden of Gout in the Veterans Health Administration. Arthritis Care Res (Hoboken). 2021. PMID: 32475070. doi:10.1002/acr.24339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。